Cancer of unknown primary

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Cancer of unknown primary is a heterogeneous syndrome rather than one biological disease. A metastatic deposit is identified, but the site of origin remains occult after a defined assessment. Some primaries are small, regressed or difficult to visualise; others lose organ-specific differentiation. The immediate questions are whether the tissue is truly malignant, which broad lineage it represents, whether a treatable site or favourable subset is present and whether further testing will change management.

NICE recommends a focused initial evaluation: comprehensive history and examination, full blood count and biochemistry, urinalysis, symptom-directed tests, and CT chest, abdomen and pelvis, with biopsy and immunohistochemistry. Additional endoscopy, breast imaging, PET-CT, germ-cell markers, CA125 or PSA is used selectively. A marker elevation alone rarely establishes origin because many rise in several cancers and benign illness.

Management depends on pathology, molecular findings with validated relevance, distribution, performance status, symptoms and preferences. Local therapy can help solitary or favourable-pattern disease; empiric systemic therapy may be considered for fit patients without a site-specific route. Early palliative care treats pain, breathlessness, nausea, psychological distress and planning needs alongside any tumour-directed option.

Key points

Malignancy of undefined primary describes metastatic cancer before a full initial assessment; confirmed cancer of unknown primary remains after appropriate investigation fails to identify origin.
First confirm malignancy and lineage with adequate tissue; poorly planned broad imaging or tumour markers cannot substitute for pathology.
History, full examination, basic blood tests and contrast CT chest, abdomen and pelvis form the initial diagnostic core under NICE guidance.
Immunohistochemistry is used stepwise to establish broad lineage and support plausible origin, conserving tissue for treatment-relevant tests.
Routine indiscriminate tumour-marker panels, endoscopies and repeated imaging have low specificity and create false leads; add tests only when clinical or pathological evidence points to a site.
Recognise favourable subsets with site-specific treatment potential, including selected nodal, peritoneal, bone or germ-cell patterns.
Discuss prognosis and treatment intent early; some patients benefit from systemic therapy, local control or trials while others are best served by symptom-focused care.
A named CUP multidisciplinary team should coordinate results, prevent duplicated tests and integrate palliative care from diagnosis.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Occult small primary

The primary tumour may remain below imaging resolution while biologically capable metastatic clones establish clinically visible disease elsewhere.

Regressed or anatomically hidden origin

Some primaries involute, arise in difficult-to-image mucosal sites or are obscured by metastatic burden and treatment-related change.

Loss of differentiation

Advanced tumour evolution can reduce organ-specific morphology and marker expression, making the original tissue lineage difficult to identify confidently.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Metastatic competence develops
Tumour clones acquire invasive, vascular-survival and tissue-colonisation abilities that allow distant disease despite a clinically occult primary.
2
Organ pattern reflects biology
Routes of lymphatic and blood flow, tumour adhesion and tissue microenvironment shape whether metastases appear in nodes, liver, lung, bone or peritoneum.
3
Heterogeneity complicates classification
Metastatic deposits can differ genetically and phenotypically from the primary, while poorly differentiated cells lose the markers normally used to infer origin.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Metastatic adenocarcinoma

Adenocarcinoma in liver, lung, bone, peritoneum or nodes without an evident primary is common but still requires clinicopathological correlation.

Favourable nodal pattern

Axillary adenocarcinoma in a woman, cervical squamous carcinoma or inguinal squamous disease may follow a site-specific pathway despite occult primary.

Peritoneal pattern

Serous papillary peritoneal disease in a woman can resemble ovarian cancer and requires gynaecological pathology and MDT assessment.

Midline germ-cell pattern

Young age, midline mass and compatible marker pattern can indicate an extragonadal germ-cell tumour with substantially different curative treatment.

Acute metastatic complicationRed flag

Neurological deficit, obstruction, severe pain, pathological fracture or metabolic deterioration requires emergency treatment before the primary is found.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Core biopsy with immunohistochemistryFirst step
Why
Confirm malignancy, lineage and a plausible organ profile while preserving tissue.
Interpretation and limitations
Use a staged panel guided by morphology; excessive stains can exhaust material and false specificity can misassign a primary.
02
Contrast CT chest abdomen pelvis
Why
Identify a primary, disease distribution, complications and a safe biopsy target.
Interpretation and limitations
Review patterns with specialist radiology; absence of a primary after adequate CT supports CUP but does not define tumour biology.
03
Full blood count and biochemical profile
Why
Assess organ function, calcium, liver pattern and treatment safety.
Interpretation and limitations
Abnormalities can indicate complication or distribution but are not organ-specific; severe hypercalcaemia or cytopenia may need immediate treatment.
04
Selective tumour markers
Why
Support a small number of clinically plausible favourable diagnoses.
Interpretation and limitations
Use PSA, germ-cell markers or CA125 only in the relevant presentation; broad panels create non-specific elevations and diagnostic cascades.
05
Targeted endoscopy, MRI or PET-CT
Why
Resolve a specific site hypothesis or potentially curable limited pattern.
Interpretation and limitations
Order when symptoms, histology or distribution support the question and the result would change treatment; it is not routine completion testing for everyone.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Lymphoma

Nodal, marrow or extranodal lymphoma can mimic metastatic carcinoma but requires haematological immunophenotyping and a completely different treatment pathway.

Metastatic melanoma

Amelanotic melanoma may resemble undifferentiated carcinoma; skin examination and melanocytic markers establish lineage when morphology is unclear.

Germ-cell tumour

A young person with midline disease and compatible markers may have a highly treatable germ-cell malignancy rather than unfavourable CUP.

Multiple primary cancers

More than one tumour can coexist, so discordant morphology or distribution should not be forced into a single occult-primary explanation.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01StabiliseTreat urgent metastatic harmFirst stepThe patient has neurological, obstructive, metabolic, haemorrhagic or infective compromise.

1Use ABCDE assessment and activate acute oncology plus the organ-specific emergency team before completing primary-site investigation.
2Obtain the targeted urgent imaging and begin indicated rescue, analgesia and thrombosis or infection management without awaiting every pathology addendum.
3Choose any urgent biopsy or intervention collaboratively so it can also support later diagnosis without compromising immediate safety.

02DefineComplete the initial CUP assessmentMetastatic malignancy is suspected and the patient is stable enough for investigation.

1Take a complete exposure, family and symptom history; examine skin, nodes, breast, rectal, pelvic, testicular and other sites as clinically appropriate.
2Perform baseline blood tests, contrast CT chest-abdomen-pelvis and an adequate core biopsy with staged immunohistochemistry.
3Present findings at the CUP MDT to classify malignancy, identify favourable subsets and decide which focused additional test could alter treatment.

03TreatAlign therapy with biology and goalsThe primary remains unidentified after appropriate focused assessment.

1Use a site-specific pathway when clinicopathological evidence is sufficiently coherent; otherwise discuss empiric systemic, local or trial options based on likely benefit.
2Assess performance status after reversible complications are treated and explain uncertainty, expected burden and alternatives in absolute terms.
3Integrate palliative care, symptom control and advance planning from diagnosis, reviewing whether each further investigation remains capable of changing care.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Metastatic organ failure

Progressive liver, lung, marrow, brain or skeletal involvement can cause jaundice, breathlessness, cytopenias, neurological loss, fracture and severe pain.

Diagnostic burden

Repeated non-directed scans, endoscopies and biopsies create procedural harm, incidental findings and delay without necessarily improving treatment selection.

Psychological uncertainty

Not knowing the cancer's origin can intensify distress and complicate prognostic discussion, requiring clear communication and consistent clinical ownership.

Treatment toxicity without benefit

Empiric therapy can harm when lineage, organ reserve, performance status or realistic goals have not been defined carefully.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Maintain one CUP results timeline covering pathology, immunohistochemistry, molecular addenda, imaging and MDT decisions to prevent repeated low-yield testing.
Reassess pain, neurological function, nutrition, performance status and organ complications at every contact because clinical need may change faster than diagnostic certainty.
During anticancer treatment, monitor regimen-specific blood counts, renal, hepatic and toxicity parameters and provide 24-hour acute-oncology contact.
Review whether further tests remain decision-changing after each result, stopping investigations that cannot improve treatment or symptom planning.
Document preferred place of care, escalation decisions and family communication while preserving the option to revise goals as disease evolves.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Unknown is not uninvestigated

CUP is assigned after an appropriate focused assessment, not simply because the first scan fails to show a primary.

Lineage comes first

Distinguishing carcinoma, lymphoma, melanoma, sarcoma and germ-cell tumour changes the entire pathway before organ origin is debated.

Markers create noise

Non-specific tumour-marker elevations are common in metastatic and benign disease and can generate misleading site labels.

Favourable subsets matter

A small minority has biology or distribution that supports site-specific and sometimes curative-intent treatment.

Stopping tests is active care

When no result can alter treatment or goals, avoiding further invasive investigation reduces harm and creates time for symptom control.

11Common pitfallsFrequent interpretation and management errors.

01
Calling metastatic disease CUP before adequate tissue.
02
Ordering every available tumour marker.
03
Exhausting biopsy tissue on broad stains.
04
Delaying an emergency while looking for the primary.
05
Ignoring a favourable clinicopathological subset.
06
Repeating imaging without a decision question.
07
Equating palliative care with no active treatment.